Valproic Acid Should NOT Be Used for ASPD or BPD
Valproic acid is not recommended for treating Antisocial Personality Disorder (ASPD) or Borderline Personality Disorder (BPD), primarily due to severe teratogenic risks that outweigh any modest symptomatic benefits, and the lack of robust evidence supporting its use for these specific conditions.
Critical Safety Concerns Override Potential Benefits
The FDA explicitly warns that valproic acid causes major congenital malformations and decreased IQ in offspring when used by women of childbearing potential 1. The drug label states unequivocally: "valproate should not be administered to a woman of childbearing potential unless the drug is essential to the management of her medical condition. This is especially important when valproate use is considered for a condition not usually associated with permanent injury or death (e.g., migraine)" 1.
Both BPD and ASPD fall into this category—they are not conditions typically associated with permanent injury or death, making valproic acid use particularly inappropriate.
Evidence Quality is Weak for Personality Disorders
While valproic acid has established efficacy for bipolar disorder 2 and epilepsy 2, the evidence for personality disorders is substantially weaker:
For BPD:
- A 2010 Cochrane review found that valproate showed some benefit for BPD symptoms, but noted "the robustness of findings is low, since they are based mostly on single, small studies" 3
- The most recent data from 2024 shows that prescribing practices have appropriately decreased valproate use in women of childbearing age with BPD—from 10% in 2014 to 6% in 2019—specifically in response to safety warnings 4
- The 2024 study explicitly states: "we echo warnings against off-label prescribing of sodium valproate in borderline personality disorder" 4
For ASPD:
- No evidence exists in the provided literature supporting valproic acid use specifically for ASPD
- The only ASPD-related research focuses on neurobiological markers, not treatment efficacy 5
What the Evidence Actually Shows
The limited positive findings come from:
- One small open-label trial from 1995 with only 8 completers, showing 50% response rate for overall improvement 6
- A 2011 review suggesting valproate "can be useful" but acknowledging the need for "further studies to improve methods of trials and confirm these findings" 7
- A 2018 follow-up study showing some sustained benefit for anger control when combined with omega-3 fatty acids 8
These modest benefits for specific symptoms (irritability, impulsivity, anger) do not justify the severe teratogenic risks, especially given that both BPD and ASPD predominantly affect individuals of childbearing age.
Clinical Algorithm
For women of childbearing potential with BPD or ASPD:
- Do not prescribe valproic acid
- Consider alternative mood stabilizers with better safety profiles (lamotrigine, lithium with appropriate monitoring)
- Consider second-generation antipsychotics (aripiprazole, olanzapine) for specific symptom clusters 3, 7
- Prioritize evidence-based psychotherapy (dialectical behavior therapy for BPD)
For men or women beyond childbearing age:
- Valproic acid remains inappropriate as first-line treatment due to weak evidence
- If considering for severe impulsivity/aggression unresponsive to other treatments, target specific symptoms rather than the personality disorder diagnosis itself
- Monitor closely for hepatotoxicity, pancreatitis, and other serious adverse effects 1
Common Pitfalls to Avoid
- Do not prescribe valproic acid off-label for personality disorders in women of childbearing potential—the risk-benefit ratio is unacceptable 1, 4
- Do not assume efficacy in bipolar disorder translates to personality disorders—these are distinct conditions with different pathophysiology
- Do not rely on outdated small studies from the 1990s when current practice guidelines and safety data clearly advise against this use 4
The trend toward decreased prescribing represents appropriate clinical practice evolution in response to safety concerns 4.